Patients in the UK diagnosed with Chronic Obstructive Pulmonary Disease (COPD), an incurable lung condition affecting an estimated 1.7 million people, now have access to a groundbreaking injection that can help prevent severe, life-threatening flare-ups. The drug, known as dupilumab, has demonstrated the ability to reduce the frequency of these exacerbations, which often involve worsening symptoms like shortness of breath and coughing, by one-third.
The new treatment, approved by the National Institute for Health and Care Excellence (NICE) last year, was administered to its first COPD patients on the National Health Service (NHS) last week. Experts anticipate that dupilumab could lead to a substantial decrease in COPD-related deaths and hospital admissions, which currently impose an annual cost of approximately £2 billion on the health service.
Traditionally, COPD is managed with inhalers and steroids, with lifestyle changes such as exercise and diet also recommended to lower exacerbation risk. However, research indicates that many COPD patients have a life expectancy of no more than a decade following diagnosis.
Dupilumab functions by targeting specific proteins in the body responsible for inflammation. This action helps to reduce swelling in the airways and decrease mucus buildup, thereby improving a patient's ability to breathe. Helen Knight, director of medicines evaluation at NICE, stated that dupilumab offers an effective, targeted therapy with impressive results in reducing flare-ups and enhancing lung function. She added that the treatment provides genuine hope for a better quality of life for patients and benefits the NHS.
Patrick Regan, a 67-year-old from Catford, south-east London, was among the first patients to receive dupilumab. Diagnosed with COPD 15 years ago, Regan expressed his eagerness to try the medication, hoping it would improve his breathing and overall well-being. He noted that COPD significantly impacts his ability to engage in activities like walking and spending time with his family, making the new medication a crucial option for him.